Ellie Bruni’s Post

CPHI Middle East to propel region's biotech and pharma innovation Industry pioneers and thought-leaders from over 100 countries will gather in Riyadh this December, marking the inaugural edition of the region's most comprehensive pharma convergence

CPHI survey ranks India as fastest-growing region

Why Saudi Arabia is the Next Hub for Biotech and Pharma Companies: Insights from CPHI Riyadh Attending the recent CPHI Conference in Riyadh highlighted the immense potential Saudi Arabia holds for the biotech and pharmaceutical industries. As the Kingdom continues its transformative journey under Vision 2030, it’s clear that the region is positioning itself as a global leader in healthcare innovation and pharmaceutical excellence. Here’s why Saudi Arabia is becoming an increasingly attractive destination for biotech and pharma companies: 1. Strategic Vision and Government Support Vision 2030 emphasizes the development of a robust healthcare sector. With substantial government investments and initiatives aimed at fostering research and development, Saudi Arabia is creating an ecosystem that encourages innovation and collaboration in biotech and pharmaceuticals. 2. State-of-the-Art Infrastructure From advanced manufacturing facilities to research hubs, the Kingdom has invested in building world-class infrastructure to support the life sciences sector. This infrastructure not only enhances local production but also facilitates global partnerships. 3. Growing Market Demand With a rapidly expanding population and an increasing focus on chronic disease management, the demand for innovative therapeutics is at an all-time high. Saudi Arabia provides a unique opportunity for companies to tap into a high-growth market. 4. Regulatory Advancements The regulatory framework in Saudi Arabia has evolved to streamline approvals, making it easier for companies to introduce innovative products while ensuring patient safety. 5. Global Partnerships Events like CPHI Riyadh underscore the Kingdom’s commitment to fostering international collaborations. These platforms allow stakeholders to exchange knowledge, explore opportunities, and drive advancements in healthcare. Saudi Arabia is not just an emerging market; it’s a strategic partner for companies looking to innovate and grow in the biotech and pharma space. The discussions and insights from CPHI Riyadh reinforced the Kingdom’s immense potential. What are your thoughts on Saudi Arabia’s potential as a global leader in biotech and pharma? Feel free to share your insights or reach out if you’d like to discuss more. #CPHI2024 #Vision2030 #Biotech #Pharma #SaudiArabia #Innovation #HealthcareTransformation

In addition to the keynote at CPHI Middle East this week, our co-founder and CTO Thrasyvoulos Karydis will be on the panel “Exploring AI Potential in Pharma for Drug Discovery and Development" this Thursday, Dec 12. 🧬🧬 Moderated by Dean Calhoun, CIH, President/CEO of Affygility Solutions, with Thras and Majd Abdulghani, PhD, genomics lead at Lean Business Services and Saudi Arabia's first Rhodes Scholar. The panel will delve into the latest developments in AI-driven drug discovery and the impact of artificial intelligence on development timelines, & future possibilities for AI in pharmaceutical innovation collaborative opportunities in the Middle East's growing biotech sector. About CPHI Middle East 2024 CPHI Middle East 2024 will bring together over 400 exhibitors and 30,000 visitors from 100+ countries, focusing on pharmaceutical innovations, networking, and market opportunities in the Middle East. With more than 150 speakers and a backdrop of Saudi Arabia’s rapidly growing pharmaceutical market (projected to reach USD 12.1 billion), this gathering represents a significant opportunity for industry leaders to connect, learn, and drive forward pharmaceutical advancements in the region. More info here: 👇👇 https://lnkd.in/g67VB2fW

After seeing lots of posts about CPhI, I am excited to share some facts about this incredible event and why it's such a key platform for the global pharmaceutical industry. CPhI Worldwide is not just another trade show. It’s the event where the pharmaceutical world comes together to network, explore innovations, and form partnerships that drive the future of the industry. Milan, a hub of life sciences, is the perfect backdrop for such a gathering of industry professionals. So, why is CPhI so important? Global Networking: With attendees from over 140 countries, it’s an unmatched opportunity for pharma companies, CROs, and service providers to meet under one roof, making connections that lead to business deals and collaborations. Product Launches & Innovation: Companies often choose CPhI to showcase their latest advancements in APIs, biologics, and drug delivery systems. It’s where cutting-edge research meets real-world application. Knowledge Exchange: Thought leaders, regulatory experts, and industry veterans share insights into emerging trends, from sustainability in pharma manufacturing to digital transformation. in this Cphi Milan the expected visitors will be 62000, 2400 company & 180 international speakers What does it cost to be part of this? Exhibitors pay between ₹4.4 lakh to ₹52.8 lakh for booths, depending on size and location, with additional services adding to the total cost. Attendees, however, get priceless opportunities to learn from workshops, expand their global reach, and form partnerships that can redefine their business. What are the outcomes? Business Growth: CPhI drives the growth of pharmaceutical companies by facilitating deal-making, expanding market reach, and fostering partnerships. Insight into Future Trends: From sustainability to digital innovation, the knowledge gained at CPhI helps shape the strategies of tomorrow. Brand Visibility: Companies can boost their global visibility, with some even launching breakthrough products and services at the event. CPhI is more than just an event – it’s where the future of pharma is built. Excited to see what innovations come out of this year's edition in Milan! #CPhIWorldwide #Pharmaceuticals #PharmaInnovation #PharmaMarketing #Networking #B2BEvents #Pharma

🌟 2025 Event Schedule for the Pharma & Biotech Industries! 🌟 Dear friends, colleagues, and partners, As we gear up for 2025, I would like to share a lineup of key global events in the pharmaceutical, biotech, CRO, and healthcare sectors. These events are not just opportunities to learn and grow but also perfect platforms for collaboration, networking, and innovation. Here’s a snapshot of the must-attend events: 1️⃣ EUCROF Conference – Copenhagen, Denmark (Feb 2–4) Collaboration and insights into clinical trial management. 2️⃣ Bio Europe Spring – Milan, Italy (Mar 17–19) Global networking for pharma, biotech, and finance professionals. 3️⃣ DIA Europe – Basel, Switzerland (Mar 18–20) Focus on drug development, regulations, and patient safety. 4️⃣ MedTech Europe Forum – Lisbon, Portugal (May 13–15) Explore trends and regulations in the medical device industry. 5️⃣ ICH Conference – Madrid, Spain (May 13–14) Harmonizing global drug development and approval processes. 6️⃣ EACPT Congress – Helsinki, Finland (Jun 28–Jul 1) Latest advancements in clinical pharmacology and therapeutics. 7️⃣ World Drug Safety Congress Europe – Amsterdam, Netherlands (Oct 7–8) Deep dive into drug safety and pharmacovigilance. 8️⃣ ESMO Congress – Berlin, Germany (Oct 17–21) Showcasing the latest in cancer research and therapies. 9️⃣ CPhI Worldwide – Frankfurt, Germany (Oct 28–30) The world’s largest pharma and biotech exhibition. 🔟 BIO-Europe – Vienna, Austria (Nov 3–5) Europe’s biggest partnering event for pharma and biotech. --- 💡 Let’s Meet and Collaborate! Whether it's to exchange ideas, discuss potential partnerships, or simply catch up, let’s make the most of these opportunities together. Looking forward to hearing from you all. 🙌 #Pharma #Biotech #CRO #Networking #Innovation #Collaboration #CNRRESEARCH

✨ Namaste Global Heads to CPHI North America: Bridging the Gap for Indian Healthcare in the US Market! ✨ We as Namaste Global will be attending CPHI North America, the premier pharmaceutical event, happening 07 – 09 May in Philadelphia! Our founder, 📢 Sanchit Sharma, and our team of 💊 scientific experts are eager to connect with industry leaders, explore the latest advancements in biopharma, and showcase how Namaste Global empowers Indian healthcare companies to seamlessly enter and thrive in the US market. Are you an Indian CDMO looking to expand your reach? CPHI provides the perfect platform to connect with potential US partners and unlock new growth opportunities. We understand the challenges CDMOs face in navigating the US market, and our team is here to help! At CPHI, we'll be discussing: ⭐ Strategies for Indian CDMOs to successfully enter the US market. ⭐ Building strategic partnerships with US pharmaceutical companies. ⭐ Leveraging Namaste Global's expertise to overcome regulatory hurdles and cultural differences. Connect with us! We'd love to discuss your specific needs and how Namaste Global can help you achieve your US expansion goals. Schedule your meet with us between May 7 – 9 by writing to us at info@namasteglobal.co or comment below. #CPHI #NorthAmerica #Pharma #CDMO #India #USA #Healthcare #MarketEntry #Partnerships

🚀Expanding Horizons: AstraZeneca doubles its bet in #Barcelona #Catalonia Rick R. Suárez, President of AstraZeneca Spain, announced that the British pharmaceutical company has doubled its commitment to the R&D hub in Barcelona: it will reach 2,000 jobs, compared to the 1,000 announced exactly a year ago, with an investment of 1.3 billion, which is 500 million more than initially planned when the initiative was announced. 📍 Why Barcelona? Renowned for its strong foundation in scientific research, Barcelona now concentrates the densest health company ecosystem in Europe, offering thus a unique environment for biotechnological advancements. As mentioned by the company, the main reasons for its investment in Catalonia were: 1) Access to highly qualified talent 2) Access to cutting-edge research facilities, and collaborative opportunities 3) Strong support from the Catalan and Spanish institutions 4) Strong biotech ecosystem & existing pharmaceutical hub 🔬 Innovation and Collaboration at Its Core AstraZeneca's R&D hub aims to become an excellent reference centre for clinical innovation in Europe. The facility will coordinate international projects across the company's main therapeutic areas: oncology, cardiovascular, renal, and metabolic diseases, respiratory diseases, vaccines and immunotherapies, and rare diseases. 🤝 Boost for Catalonia's Health Sector This expansion is more than just a corporate milestone; it's a massive growth for Catalonia's health sector, as it promises: - Enhanced job opportunities in high-tech and pharmaceutical fields. - Strengthened partnerships with local research institutes and universities. - A boost to the local economy through increased investment in healthcare infrastructure. #AstraZeneca #Innovation #Research #Healthcare #Pharmaceuticals #GlobalHealth #Expansion #FDI #Foreigndirectinvestment #Inwardinvestment #Healthcare Catalonia Trade & Investment CataloniaBio & HealthTech Biocat, BioRegion of Catalonia Barcelona Health Hub

#Africa and #MENA 🌍✨can leapfrog 🚀 in digital/AI healthcare. With fewer rigid structures and a youthful, increasingly tech-savvy population, these regions have the potential for rapid adoption of cutting-edge technologies. This isn't just about catching up; it's about developing emerging technologies for regional and local healthcare needs. At this week's #DigitalHealthcare Innovation Conference in sunny ☀️🌴 Casablanca, MENA and African innovation will be showcased covering: - #Healthtech startup pitching competition - AI/ML-enabled #DrugDiscovery - #ML and #ComputerVision-based #diagnostics - Digital solutions for #HealthcareInequities - Digital #MentalHealthcare - #Robotics, AI, #telemedicine, #IoMT in healthcare - #DigitalRestructuring of healthcare organisations - #BigData, #privacy and digital health sovereignty Looking forward to witnessing a regional take on vaulting ahead in this exciting space! 🌍✨🚀🧬🩺 fellow panelists and startup judges at 2 sessions: Salim Chemlal, Ph.D. | Dr Radouane Oudrhiri | Mohamed El Bouhmadi | Dr Othmane BOUMAALIF | Mehdi Seqat | Imane Bara, PhD | Adam Skali | Bassma JIOUDI